Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer-A Literature Review.

Danilo Giffoni de Mello Morais Mata Carlos Amir CarmonaAndrea EisenMaureen E Trudeau

Published in: Current oncology (Toronto, Ont.) (2022)

Classifying the risk category assists in deciding the treatment route and its optimal duration. Tailoring the breadth of ET hinges on a wide array of factors to be appraised for each individualized case, including weighing its benefits and harms.

Keyphrases

early stage
case report
high resolution
high throughput
combination therapy
mass spectrometry
breast cancer risk